This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gurova, K. V. Articles by Gudkov, A. V. Search for Related Content PubMed PubMed Citation Articles by Gurova, K. V. Articles by Gudkov, A. V.

p53 Pathway in Renal Cell Carcinoma Is Repressed by a Dominant Mechanism

¹ Department of Molecular Biology, Lerner Research Institute, The Cleveland Clinic Foundation, Cleveland, Ohio, and ² Department of Molecular Genetics, University of Illinois at Chicago, Chicago, Illinois

Renal cell carcinoma (RCC) rarely acquires mutations in p53 tumor suppressor gene, suggesting that p53 signaling in this tumor type might be repressed by some other mechanism. In fact, all four RCC-derived cell lines we tested maintained wild-type p53 but were not capable of transactivating p53-responsive reporters and endogenous p53-responsive genes. p53 protein in RCC showed normal response to genotoxic stress, including accumulation, nuclear translocation, and activation of specific DNA binding. Functional and expression analysis of Mdm2, MdmX, and Arf showed lack of involvement of these p53 regulators in the observed defect of p53 function in RCC. However, activation of p53-mediated transactivation could be achieved by extremely high levels of p53 attained by lentivirus vector-driven transduction, suggesting the involvement of a dominant inhibitor in repression of p53-dependent transactivation in RCC. Consistently, p53 inactivation prevailed in the hybrids of RCC cells with the cells possessing fully functional p53. Remarkably, cells of normal kidney epithelium also caused partial p53 repression in cell fusion experiments, suggesting that RCC-specific p53 repression may be based on an unknown dominant mechanism also acting in normal kidney tissue.

This article has been cited by other articles:

				J. A. Bertout, A. J. Majmundar, J. D. Gordan, J. C. Lam, D. Ditsworth, B. Keith, E. J. Brown, K. L. Nathanson, and M. C. Simon HIF2{alpha} inhibition promotes p53 pathway activity, tumor cell death, and radiation responses PNAS, August 25, 2009; 106(34): 14391 - 14396. [Abstract] [Full Text] [PDF]

				C. M. Kinney, U. M. Chandrasekharan, L. Yang, J. Shen, M. Kinter, M. S. McDermott, and P. E. DiCorleto Histone H3 as a novel substrate for MAP kinase phosphatase-1 Am J Physiol Cell Physiol, February 1, 2009; 296(2): C242 - C249. [Abstract] [Full Text] [PDF]

				H. Wang, A. Matsuzawa, S. A. Brown, J. Zhou, C. S. Guy, P.-H. Tseng, K. Forbes, T. P. Nicholson, P. W. Sheppard, H. Hacker, et al. Analysis of nondegradative protein ubiquitylation with a monoclonal antibody specific for lysine-63-linked polyubiquitin PNAS, December 23, 2008; 105(51): 20197 - 20202. [Abstract] [Full Text] [PDF]

				M. Garg, D. Kanojia, A. Khosla, N. Dudha, S. Sati, D. Chaurasiya, N. Jagadish, A. Seth, R. Kumar, S. Gupta, et al. Sperm-Associated Antigen 9 Is Associated With Tumor Growth, Migration, and Invasion in Renal Cell Carcinoma Cancer Res., October 15, 2008; 68(20): 8240 - 8248. [Abstract] [Full Text] [PDF]

				V. A. Carroll and M. Ashcroft Regulation of Angiogenic Factors by HDM2 in Renal Cell Carcinoma Cancer Res., January 15, 2008; 68(2): 545 - 552. [Abstract] [Full Text] [PDF]

				J. Friedman, L. Nottingham, P. Duggal, F. G. Pernas, B. Yan, X. P. Yang, Z. Chen, and C. Van Waes Deficient TP53 Expression, Function, and Cisplatin Sensitivity Are Restored by Quinacrine in Head and Neck Cancer Clin. Cancer Res., November 15, 2007; 13(22): 6568 - 6578. [Abstract] [Full Text] [PDF]

				I. Talon, V. Lindner, C. Sourbier, E. Schordan, S. Rothhut, M. Barthelmebs, H. Lang, J.-J. Helwig, and T. Massfelder Antitumor effect of parathyroid hormone-related protein neutralizing antibody in human renal cell carcinoma in vitro and in vivo Carcinogenesis, January 1, 2006; 27(1): 73 - 83. [Abstract] [Full Text] [PDF]

				S. A.J. Vaziri, J. Hill, K. Chikamori, D. R. Grabowski, N. Takigawa, M. Chawla-Sarkar, L. R. Rybicki, A. V. Gudkov, T. Mekhail, R. M. Bukowski, et al. Sensitization of DNA damage-induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3{sigma} and survivin Mol. Cancer Ther., December 1, 2005; 4(12): 1880 - 1890. [Abstract] [Full Text] [PDF]

				K. V. Gurova, J. E. Hill, C. Guo, A. Prokvolit, L. G. Burdelya, E. Samoylova, A. V. Khodyakova, R. Ganapathi, M. Ganapathi, N. D. Tararova, et al. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-{kappa}B-dependent mechanism of p53 suppression in tumors PNAS, November 29, 2005; 102(48): 17448 - 17453. [Abstract] [Full Text] [PDF]

				J. T. Marques, D. Rebouillat, C. V. Ramana, J. Murakami, J. E. Hill, A. Gudkov, R. H. Silverman, G. R. Stark, and B. R. G. Williams Down-Regulation of p53 by Double-Stranded RNA Modulates the Antiviral Response J. Virol., September 1, 2005; 79(17): 11105 - 11114. [Abstract] [Full Text] [PDF]

				H. E. Warburton, M. Brady, N. Vlatkovic, W. M. Linehan, K. Parsons, and M. T. Boyd p53 Regulation and Function in Renal Cell Carcinoma Cancer Res., August 1, 2005; 65(15): 6498 - 6503. [Abstract] [Full Text] [PDF]